A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may ...

Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably ...

New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular lymphoma can achieve durable, multi-year remission with chimeric antigen receptor ...

In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety ...

A retrospective real-world analysis presented at the 2025 ASH Annual Meeting and Exposition showed that circulating tumor DNA (ctDNA) detected at the end of treatment (EOT) was a prognostic indicator ...

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients ...

Stable survival rates were observed for HIV-associated lymphoma patients during the antiretroviral therapy (ART) era in the US, according to a new study published July 26 in the Journal of the ...

Zanubrutinib combined with R-CHOP showed high efficacy in DLBCL patients with activated BCR signaling and specific genetic mutations, achieving a 91.4% ORR and 79.3% CR rate. The study's primary ...

There is a link between non-Hodgkin’s lymphoma (NHL) and smoking. Heavy smoking has an association with NHL, and the link is especially strong with the subtype known as follicular lymphoma. A 2017 ...